Lets all hope that holders with a substantial position in the company don't start scrambling for the exits as this could make the SPP @ 31c look expensive.
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling